Moderna新型肺炎疫苗完成接种半年後保护率仍达90%
《CNBC》报道,美国药厂Moderna(MRNA.US)周二(13日)表示,其研发的新型肺炎疫苗在接种第二剂半年後的保护率仍超过90%,对重症的保护率更超过95%。而最新截至4月9日的数据评估了900多个病例,其中包括百多个严重病例。
是次更新数据令Moderna更接近获得美国全面批准该疫苗的要求,当局全面批准疫苗需要更严格的审查流程,以证明疫苗对其预期用途是安全有效。一旦获得全面批准,Moderna可开始向消费者直接销售疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.